-
07 May 2025 18:22:10
- Source: Sharecast
GSK plc
Results of 25th Annual General Meeting
GSK plc ('GSK') held a hybrid Annual General Meeting ('AGM') at 2.30pm on Wednesday 7 May 2025 at The Landmark London, 222 Marylebone Road, London, NW1 6JQ. Shareholders were able to join the meeting in person or virtually via the Lumi AGM website and Zoom.
All valid proxy votes (whether submitted electronically or in hard copy form) were included in the poll taken at the meeting.
All 25 resolutions were passed and decided upon by a poll. The table below shows the results for each resolution. The full text of the resolutions is contained in the Notice of AGM published on 24 March 2025, which is available on GSK's website at www.gsk.com.
|
Resolution |
Total votes for(1)(2) |
% |
Total votes against(2) |
% |
Total votes cast |
% of Issued Share Capital voted(3) |
Votes withheld(4) |
|
|
1 |
Receive and adopt the 2024 Annual Report |
3,031,647,740 |
99.82 |
5,472,209 |
0.18 |
3,037,119,949 |
73.91% |
12,204,390 |
|
2 |
Approve the Annual report on remuneration |
2,810,183,626 |
92.46 |
229,176,108 |
7.54 |
3,039,359,734 |
73.97% |
9,979,421 |
|
3 |
Approve the Remuneration policy |
2,786,567,742 |
93.10 |
206,384,696 |
6.90 |
2,992,952,438 |
72.84% |
56,376,703 |
|
4 |
Election of Dr Gavin Screaton |
3,040,206,238 |
99.89 |
3,385,136 |
0.11 |
3,043,591,374 |
74.07% |
5,719,426 |
|
5 |
Re-election of Sir Jonathan Symonds |
2,947,917,394 |
98.40 |
48,075,530 |
1.60 |
2,995,992,924 |
72.91% |
53,319,043 |
|
6 |
Re-election of Dame Emma Walmsley |
3,038,248,728 |
99.82 |
5,613,533 |
0.18 |
3,043,862,261 |
74.08% |
5,444,311 |
|
7 |
Re-election of Julie Brown |
3,034,344,765 |
99.69 |
9,515,889 |
0.31 |
3,043,860,654 |
74.08% |
5,460,463 |
|
8 |
Re-election of Elizabeth McKee Anderson |
2,941,679,748 |
96.64 |
102,161,424 |
3.36 |
3,043,841,172 |
74.08% |
5,465,676 |
|
9 |
Re-election of Charles Bancroft |
2,956,308,387 |
97.13 |
87,450,752 |
2.87 |
3,043,759,139 |
74.07% |
5,553,709 |
|
10 |
Re-election of Dr Hal Barron |
3,039,339,475 |
99.85 |
4,466,176 |
0.15 |
3,043,805,651 |
74.08% |
5,489,801 |
|
11 |
Re-election of Dr Anne Beal |
2,955,431,838 |
97.09 |
88,492,673 |
2.91 |
3,043,924,511 |
74.08% |
5,388,566 |
|
12 |
Re-election of Wendy Becker |
2,933,164,994 |
96.36 |
110,745,350 |
3.64 |
3,043,910,344 |
74.08% |
5,400,009 |
|
13 |
Re-election of Dr Harry C Dietz |
3,039,383,688 |
99.86 |
4,369,000 |
0.14 |
3,043,752,688 |
74.07% |
5,560,851 |
|
14 |
Re-election of Dr Jeannie Lee |
3,039,577,387 |
99.86 |
4,161,377 |
0.14 |
3,043,738,764 |
74.07% |
5,574,652 |
|
15 |
Re-election of Dr Vishal Sikka |
3,038,858,707 |
99.84 |
4,756,490 |
0.16 |
3,043,615,197 |
74.07% |
5,688,803 |
|
16 |
Re-appointment of the auditor |
3,025,673,462 |
99.89 |
3,223,574 |
0.11 |
3,028,897,036 |
73.71% |
20,430,064 |
|
17 |
Remuneration of the auditor |
3,039,931,435 |
99.88 |
3,782,302 |
0.12 |
3,043,713,737 |
74.07% |
5,591,584 |
|
18 |
Authority for the company to make donations to political organisations and incur political expenditure |
2,946,755,927 |
99.01 |
29,581,561 |
0.99 |
2,976,337,488 |
72.43% |
72,977,673 |
|
19 |
Authority to allot shares |
2,899,903,495 |
95.30 |
143,133,156 |
4.70 |
3,043,036,651 |
74.06% |
6,282,441 |
|
20 |
Disapplication of pre-emption rights - general power(5) |
2,941,521,597 |
96.72 |
99,811,731 |
3.28 |
3,041,333,328 |
74.02% |
7,942,085 |
|
21 |
Disapplication of pre-emption rights - in connection with an acquisition or specified capital investment(5) |
2,962,038,875 |
97.39 |
79,351,038 |
2.61 |
3,041,389,913 |
74.02% |
7,904,048 |
|
22 |
Authority for the company to purchase its own shares(5) |
3,036,538,826 |
99.83 |
5,280,936 |
0.17 |
3,041,819,762 |
74.03% |
7,499,989 |
|
23 |
Exemption from statement of senior statutory auditor's name |
3,022,840,749 |
99.74 |
7,951,051 |
0.26 |
3,030,791,800 |
73.76% |
18,502,136 |
|
24 |
Authority for reduced notice of a general meeting other than an AGM(5) |
2,863,892,275 |
94.11 |
179,242,127 |
5.89 |
3,043,134,402 |
74.06% |
6,172,307 |
|
25 |
Approve the adoption of the GSK Share Value Plan |
2,972,805,515 |
99.56 |
13,033,137 |
0.44 |
2,985,838,652 |
72.67% |
63,503,752 |
Notes:
(1) The "for" votes include those giving the Chair discretion.
(2) Votes "for" and "against" are expressed as a percentage of the total votes cast.
(3) The Company's issued share capital as at 2 May 2025 consisted of 4,109,037,095 shares of 31 ¼ pence each ('Ordinary Shares') excluding Ordinary Shares held in Treasury. Every shareholder has one vote for every Ordinary Share held.
(4) A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.
(5) Indicates Special Resolutions requiring a 75% majority of votes cast.
The following table provides further information on participation in the AGM:
|
|
GSK's 25th AGM (Hybrid meeting) (2025) |
GSK's 24th AGM (Hybrid meeting) (2024) |
|
Issued share capital (excluding Treasury Shares) |
4,109,037,095
|
4,314,108,510 |
|
Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares) |
74.21% |
73.11% |
|
Total shareholder population |
86,241 |
60,448 |
|
Total number of proxies lodged |
3,743 |
2,886 |
|
Number of shareholders in attendance |
130 in person 25 participated virtually |
125 in person 38 participated virtually |
|
% of shareholders who lodged proxies |
4.34% |
4.77% |
The above poll results will shortly be available on the company's website at www.gsk.com.
In accordance with Listing Rule 6.4.2 of the Financial Conduct Authority's (FCA) Listing Rules, a copy of the resolutions, other than those concerning ordinary business, will be submitted to the FCA and will, in due course, be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
V A Whyte
Company Secretary
7 May 2025
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.